Dr. John Cush RheumNow
4 years 11 months ago
JAMA reports the COVID-19 combined infection- and vaccination-induced seroprevalence estimate in May 2021 was 83.3% By May 2021, there were 2.1 SARS-CoV-2 infections per reported COVID-19 case. https://t.co/bUZ5AqYnxM
Patients with rheumatoid arthritis (RA) who had high levels of inflammation at baseline were at increased risk for later heart failure, a large cohort study found.
Registry level data of patients with immune-mediated inflammatory diseases (IMIDs) diagnosed with COVID-19 should continue their TNF inhibitor (TNFi) therapy as such patients were less likely to experience adverse COVID-19 outcomes (compared to other immunomodulatory treatments).
Dr. John Cush RheumNow
4 years 11 months ago
Pregabalin (lyrica) for Fibromyalgia 75 mg bid; may be increased to max dose 450 mg/d. (Reduce for renal dz). Indications: DM neuropathy/pain, post-herpetic neuralgia, partial seizures. Rare AE: Angioedema, low Plts, ^PR interval, rhabdo, gynecomastia https://t.co/r4cH7n9qWD
Dr. John Cush RheumNow
4 years 11 months ago
Watch: Dr. Robert Chao ( @doctorRBC ) reviews a talk given by Dr. Laura Coates entitled, "Towards personalized treatment strategies for psoriatic arthritis", presented at the virtual EULAR 2021 meeting.
https://t.co/7FmZ4BzHwp
Dr. John Cush RheumNow
4 years 11 months ago
B-cell depletion therapy with obinutuzumab, a type II anti-CD20 monoclonal antibody, in lupus nephritis patients was shown to be effective in in combination with standard lupus therapies.
https://t.co/pMXWmuJw5Y https://t.co/1raYa1vLtK
Dr. John Cush RheumNow
4 years 11 months ago
TICOSPA - Does Treat to Target Work in Spondyloarthritis?
https://t.co/ibavOjmBJd https://t.co/DseCTMRX7J
Dr. John Cush RheumNow
4 years 11 months ago
PsABio study-real-world observational study of ustekinumab vs TNF inhibitors in PsA: 868 pts: cDAPSA remission was 14.9% UST vs 19.2% TNFk and Minimal Dz Activity was 26.4% UST vs 30.8% TNFi at 6 months - both were equipotent in PsA https://t.co/RLadZa6YTI https://t.co/I7eKxD3XyI
Dr. John Cush RheumNow
4 years 11 months ago
New podcast titled Quackademia available for download wherever you get your podcasts!
https://t.co/Y6Pqko1tYm https://t.co/6RU1nuj7QU
Dr. John Cush RheumNow
4 years 11 months ago
Congratulations to friend and mentor, Dr. Stan Cohen for receiving this years ACR Gold Medal award - the highest award that the ACR can bestow. Stan was a past ACR President & has been a leading educator and researcher in rheumatology https://t.co/EJQ5tc3dhc
Dr. John Cush RheumNow
4 years 11 months ago
FDA Approves Cyltezo, the 1st INTERCHANGEABLE Biosimilar to Humira - interchangeable means this biosimilar may be substituted for the Humira without the prescriber notice (by pharmacy)in same way generics are substituted for brand name drugs https://t.co/xvinL7UKNU
B-cell depletion therapy with obinutuzumab, a type II anti-CD20 monoclonal antibody, in lupus nephritis patients was shown to be effective in in combination with standard lupus therapies.
Prior trials testing the utility of type I anti-CD20 antibody therapies - rituximab and ocrelizumab, failed in patients with proliferative lupus nephritis (LN).
Tight-control or treat-to-target (T2T) strategy is advocated in several diseases, but the recent TICOSPA trial in axial spondyloarthritis (axSpA) showed that T2T was not superior to usual care (UC).
Dr. John Cush RheumNow
4 years 11 months ago
Kikuchi’s Dz (AKA Kikuchi-Fujimoto dz) is rare, affects young women >men w/ recurrent necrotizing lymphadenitis (may assoc w/ SLE, MAS, TB); Sx included fever, flu-Sxs, Wt loss, night sweats, Hi CRP/LFTs, lymphopenia, uncommon arthritis, organomegaly https://t.co/LpEOgbcfpP
Dr. John Cush RheumNow
4 years 11 months ago
Risk of Herpes zoster from upadacitinib RCTs: UPA > ADA > ADA+MTX > MTX. 5306 RA pts, HZ/100 Pt-Yrs was 0.8 MTX mono; 1.1 ADA+MTX; 3.0 UPA 15 mg and 5.3 UPA 30 mg. 71% of UP HZ cases involved a single dermatome. Higher risk w/ prior HZ & Asians https://t.co/0QUvXmFrJ3
